RxDoctor Payments Data

Melissa Garcia

Family · Dallas, TXNPI 1609487222

Payments from drug & device makers

$16,066in general payments, 2019–2025

Across 987 payments — averaging $16.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$1K
  • GSK$1K
  • Novo Nordisk$1K
  • Lilly USA, LLC$751
  • Amgen$733
  • plus $9K from 54 others

What the payments were for

  • Food & beverage$15,75898%
  • Education$3082%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie138$1,798
AstraZeneca64$1,417
GSK65$1,106
Novo Nordisk77$1,074
Lilly USA, LLC57$751
Amgen52$733
Pfizer36$680
Merck35$637
Boehringer Ingelheim37$558
Sumitomo Pharma America, Inc.38$551
Otsuka America Pharmaceutical, Inc.27$526
Astellas Pharma US Inc16$469
E.r. Squibb & Sons, L.L.C.22$427
Mylan Specialty L.p.30$418
Esperion Therapeutics, Inc.34$398
Kowa Pharmaceuticals America, Inc.41$340
Amarin Pharma, Inc.17$319
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC18$317
Sunovion Pharmaceuticals Inc.16$279
Dexcom, Inc.6$222
Bayer14$207
Scilex Pharmaceuticals Inc.11$193
Ironwood Pharmaceuticals, Inc11$178
Abbott3$178
Novartis9$154
Nestle Healthcare Nutrition Inc.10$144
Biohaven Pharmaceuticals, Inc.10$131
Almatica Pharma LLC6$115
Biohaven Pharmaceutical Holding Company Ltd.6$115
Shield Therapeutics Inc3$114
Genentech USA, Inc.7$109
Sanofi-aventis U.S. LLC7$107
Amneal Pharmaceuticals LLC5$99
Inspire Medical Systems, Inc.1$99
Pharming Healthcare, Inc.4$98
Vanda Pharmaceuticals Inc.3$87
Redhill Biopharma Inc.4$71
Takeda Pharmaceuticals U.S.A., Inc.3$69
Vertex3$61
Corium, LLC2$49
Antares Pharma, Inc.3$42
Exact Sciences2$38
Currax Pharmaceuticals LLC3$38
Azurity Pharmaceuticals, Inc.2$37
Corcept Therapeutics1$37
Renalytix AI, Inc.2$36
Xeris Pharmaceuticals, Inc.2$34
Alnylam Pharmaceuticals Inc.2$33
Supernus Pharmaceuticals, Inc.2$30
Avvisto Therapeutics, LLC2$29
Idorsia Pharmaceuticals US Inc2$27
Inari Medical, Inc.1$26
Eisai Inc.2$26
Arbor Pharmaceuticals, Inc.1$25
Ardelyx, Inc.1$23
Axsome Therapeutics, Inc.1$23
Aimmune Therapeutics, Inc.1$22
Clarus Therapeutics Inc.1$19
Boston Scientific1$18
Viatris Specialty LLC1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,066 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$44,001
Medicare patients
125
Services billed
491

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other family in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →